The numbers tell two completely different stories about Rocket Lab right now, and both of them are true. One version features a company stacking up government contracts at a record pace, signing launch deals for a rocket that hasn’t flown yet, and building a backlog that has never looked healthier. The other version features a stock that has shed more than half its value since May, burning through cash at a rate that would make most investors wince. Reconciling those two realities is the central challenge facing anyone who owns the shares — or is thinking about buying them.
The chart versus the order book
At last count, the stock was trading around €56, down roughly 57 percent from its 52-week high of €133.80 reached in late May. The 30-day decline alone stands at about 36 percent. Technical indicators reinforce the bearish picture: a relative strength index of 36.2, annualized volatility approaching 96 percent. On the surface, this looks like a company in serious trouble.
The business itself tells a different story. Rocket Lab’s backlog has swelled to $2.2 billion, up 20.2 percent from the previous quarter. The company holds more than $2 billion in available liquidity. In the first quarter alone, it signed 36 new launch contracts — 31 for the Electron rocket and the HASTE hypersonic test program, five for Neutron. That single quarter’s sales activity nearly matched the total number of missions flown in all of 2025.
The first-quarter results themselves were solid: revenue of $200.3 million, up 63.5 percent year over year, with a gross margin of 38.2 percent. Analysts expect second-quarter revenue of $231.6 million when results are released on August 10, with a loss of $0.06 per share.
The Pentagon keeps writing checks
The most striking development came on July 27, when Rocket Lab secured the largest single contract in its history: $266 million from the U.S. Space Force for twelve guaranteed suborbital launches under the MACH-TB 2.0 program, with options for six more. The missions, testing missile defense systems for the Pentagon and the Missile Defense Agency, will launch from Kodiak, Alaska, through 2028, with the first flight no earlier than late 2026. CEO Peter Beck’s response was characteristically terse: “Cadence, iteration, and relentless execution.”
That award extends a remarkable run of government business. The company has also landed $816 million for 18 warning satellites, $515 million for missile defense satellites, and $190 million for 20 hypersonic test flights using HASTE, which has a perfect success record on flights beyond Mach 5 since 2023. A first GEO satellite contract worth $89.5 million rounds out the portfolio. The total pipeline now exceeds 70 missions.
Commercial demand has kept pace. A five-flight deal for Neutron was signed while the vehicle has yet to make its maiden voyage. A new multi-launch agreement with Japanese company iQPS covers three additional Electron missions. A rocket that doesn’t exist yet, already booked solid — that’s not the profile of a business in structural decline.
Neutron: the delay that won’t go away
The bear case rests almost entirely on one issue: the Neutron rocket’s repeated slippage. In late February, Rocket Lab postponed the first launch after a first-stage fuel tank ruptured during testing on January 21. Beck acknowledged the setback openly but insisted the team had significantly improved the tank design, both in strength and manufacturability.
Should investors sell immediately? Or is it worth buying Rocket Lab?
Since then, the schedule has held. Rocket Lab still targets the fourth quarter of 2026 for Neutron’s debut. In April, Beck described the project as “on track,” while the Archimedes engine that will power the vehicle undergoes what he called “nasty” tests. A recent full-duration burn test ran for roughly 5.5 minutes at 1.5 million pounds of thrust — a figure Rocket Lab says is comparable to SpaceX’s Merlin 1D engine. Beck has repeatedly stressed that the company will fly “when it’s ready,” prioritizing quality over schedule commitments.
The market seems to be punishing a delay that has been stable for months as though it were a fresh, escalating crisis. That disconnect sits at the heart of the valuation debate.
The Iridium question
Adding another layer of complexity, Rocket Lab is pursuing an $8 billion acquisition of Iridium, financed through a $3.6 billion bridge loan and a cash component of $27 per share. The deal would add recurring satellite revenue to the portfolio but further strains a balance sheet that already shows negative free cash flow of $316 million over the trailing twelve months, a negative FCF margin of 46.5 percent.
The financing mechanics have arguably contributed to the share price decline, as investors digest the dilution and debt implications of the transaction. That’s a different story than a deteriorating core business — and an important distinction for anyone trying to gauge whether the sell-off represents a genuine fundamental break or a repricing of risk.
Where analysts land
Wall Street remains deeply divided. Piper Sandler downgraded the stock to “Neutral” in mid-July, triggering an 11.7 percent drop on the day. At the optimistic end, Morgan Stanley’s bull case targets $293. The broader consensus leans toward “Strong Buy,” with price targets ranging from $120 to $170. Beck’s recent sale of roughly three million shares has added fuel to the debate about fair value.
Perspective matters
Context is everything when assessing the damage. From the May peak, the decline looks catastrophic. But the stock still trades 70.86 percent above its 52-week low of €32.60 from November 2025. Investors who bought near the bottom are sitting on substantial gains. Only those who chased the euphoric May high are underwater.
The risks haven’t disappeared. Rocket Lab remains unprofitable, and the history of rocket development suggests further schedule shifts are possible. With volatility at 96 percent, sharp moves in either direction around the August 10 earnings report are the most likely outcome. But the case for a structural breakdown looks thin when the backlog is growing, government and commercial contracts are stacking up, and the Neutron timeline has held steady since spring. Earlier earnings reports have triggered violent swings in both directions, depending on whether Neutron headlines or revenue numbers dominated the narrative. Ahead of the next report, the evidence suggests looking past the short-term chart damage rather than being governed by it.
Ad
Rocket Lab Stock: Buy or Sell?! New Rocket Lab Analysis from August 3 delivers the answer:
The latest Rocket Lab figures speak for themselves: Urgent action needed for Rocket Lab investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 3.
Rocket Lab: Buy or sell? Read more here...
